searcher

U.S. Healthcare Legislation Investment Impact

Those enterprises that will profit from any increase in volume in patients and procedures would be the most likely to benefit. Abbott Labs, Covidien, Becton, Dicknson, C.R. Bard, Baxter Int'l etc.. Also, well capitalized generic drug makers. It's an ill wind that blows no one any good.

Healthcare Profits: Assessing Company Sensitivity to Obamacare

Herbal or alternative or fringe etc. medications are not the issue. Hard science pharma (or a reasonable facsimile in view of the delusional activities of quite a few R&D pharma outfits) is very very expensive and will definitely suffer. Perhaps I'm prejudiced but socialist schema tends to have a static as opposed to dynamic world view. I fear a concern with a apportioning the 'pie' will eclipse efforts to grow the 'pie'. If you think the accountants force triage healthcare now, just wait till the government has strangled the private sector with the Trojan horse of the public alternative.